Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: death; This is as spontaneous report received from a contactable Healthcare Professional downloaded from the Regulatory Authority-WEB. The regulatory authority report number is HU-OGYI-344521. A 46-year-old female patient received the first dose of BNT162B2 Pfizer-BioNTech COVID-19 mRNA Vaccine (nucleoside modified)/Tozinameran (COMIRNATY) concentrate for dispersion for injection, strength: 1 dose (0.3 mL) containing 30 micrograms of COVID-19 mRNA Vaccine, intramuscularly, in left arm, batch number: EW4815 on 17Apr2021, at 46 years of age. No events occurred after vaccination. Medical history included multiple metastatic high-grade serous ovarian carcinoma. Malignant neoplasm of lymph nodes of several regions, secondary malignancy of lung, adenocarcinoma, pancreatic metastasis. From 22Jan2021, the size and number of the lymph nodes increased. From 03Feb2021, the patient was in hospice care. In addition to severe cachexia (from 2021), Oncology 3-4 performance status developed, followed by symptomatic therapy. The patient was admitted to hospital on 07May2021 in moribund condition and died that same day at 17:55. A COVID-19 rapid test performed on 07May2021 resulted negative. Sender Comment: The patient died in metastatic high-grade serous ovarian carcinoma 20 days after COMIRNATY vaccination. There is no information whether autopsy was done. The event and COMIRNATY vaccination are not related. The case is serious due to fatal outcome. No follow-up attempts are possible. No further information is expected.; Sender''s Comments: The patient''s demise is unrelated to BNT162B2 vaccine, being rather the fatal evolution of the underlying very advanced malignancy (ovarian carcinoma).; Reported Cause(s) of Death: Neoplasm progression
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166